Editorial: Treatment for Non-Small Cell Lung Cancer in Distinct Patient Populations
- PMID: 35155265
- PMCID: PMC8828902
- DOI: 10.3389/fonc.2022.838570
Editorial: Treatment for Non-Small Cell Lung Cancer in Distinct Patient Populations
Keywords: adverse event (AE); distinct patients; non-small cell lung cancer; prognostic predictors; tailored treatment.
Conflict of interest statement
The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.
Comment on
- Editorial on the Research Topic Treatment for Non-Small Cell Lung Cancer in Distinct Patient Populations
References
-
- Howlader N, Hoone AM, Krapcho M, Miller D, Brest A, Yu M, et al. . SEER Cancer Statistics Review (1975–2016), Based on November 2018. SEER Data Submission.
-
- Garon EB, Hellmann MD, Rizvi NA, Carcereny E, Leighl NB, Ahn MJ, et al. . Five-Year Overall Survival for Patients With Advanced Non−Small-Cell Lung Cancer Treated With Pembrolizumab: Results From the Phase I KEYNOTE-001 Study. J Clin Oncol (2019) 37(28):2518–27. doi: 10.1200/JCO.19.00934 - DOI - PMC - PubMed
Publication types
LinkOut - more resources
Full Text Sources